Correction: Oncogenic  RAS -induced senescence in human primary thyrocytes: molecular effectors and inflammatory secretome involved

Maria Grazia Vizioli; Joana Santos; Silvana Pilotti; Mara Mazzoni; Maria Chiara Anania; Claudia Miranda; Sonia Pagliardini; Marco A. Pierotti; Jesus Gil; Angela Greco

doi:10.18632/oncotarget.28027

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Oncogenic RAS-induced senescence in human primary thyrocytes: molecular effectors and inflammatory secretome involved

PDF | How to cite

Oncotarget. 2022; 13:1120-1121. https://doi.org/10.18632/oncotarget.28027

Metrics: PDF 513 views | ?

Maria Grazia Vizioli^1,2, Joana Santos², Silvana Pilotti³, Mara Mazzoni¹, Maria Chiara Anania¹, Claudia Miranda¹, Sonia Pagliardini¹, Marco A. Pierotti⁴, Jesus Gil^2,* and Angela Greco^1,*

¹Molecular Mechanism Unit, Department of Experimental Oncology and Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
²Cell Proliferation Group, MRC Clinical Sciences Centre, Imperial College London, Hammersmith Campus, London, UK
³Laboratory of Molecular Pathology, Department of Pathology, IRCCS Foundation - Istituto Nazionale dei Tumori, Milan, Italy
⁴Scientific Directorate, IRCCS Foundation - Istituto Nazionale dei Tumori, Milan, Italy
^*Senior co-authors

Published: October 14, 2022

Copyright: © 2022 Vizioli et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: Due to errors during figure assembly, an incorrect blot was used for the p53 panel in Figure 3G. Additionally, the actin panel of Figure 1D is an accidental duplicate of the actin panel in Figure 2H. The corrected Figure 3G and 1D are shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2014; 5:8270–8283. DOI: https://doi.org/10.18632/oncotarget.2013

Figure 1: Oncogenic RAS triggers senescence in human primary thyrocytes. (D) Determination by western blotting of protein levels as indicated in an independent experiment; β-actin serves as loading control. The molecular weight of each protein is indicated. Data are from a representative out of two independent experiments.

Figure 3: Effect of p53 knockdown on RAS-induced senescence in primary thyrocytes. (G) Western blotting analysis for the expression of the indicated proteins performed in an independent experiment; β-actin was used as loading control; the molecular weight of each protein is shown. shp53: short hairpin targeting p53; CV: crystal violet ; IF: immunofluorescence.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28027

Publication Alerts

Corrections:

Correction: Oncogenic RAS-induced senescence in human primary thyrocytes: molecular effectors and inflammatory secretome involved